Nano-Flares for the Intracellular Detection of miRNA in Living Cells
用于活细胞内 miRNA 胞内检测的纳米耀斑
基本信息
- 批准号:7999368
- 负责人:
- 金额:$ 20万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-07-22 至 2011-07-21
- 项目状态:已结题
- 来源:
- 关键词:AndrogensBenchmarkingBindingBiologicalBiological MarkersBiological ModelsBiological SciencesBloodBone MarrowCell Culture TechniquesCell LineCell modelCell physiologyCellsClinicalCodeCollectionCommunitiesComplexConfocal MicroscopyCulture MediaDNADataDetectionDevelopmentDiagnosisDiagnosticDiseaseDoxycyclineFlareFlow CytometryFluorescenceFluorescence-Activated Cell SortingFundingGoalsGoldHealthHumanKnowledgeLabelLengthLifeMalignant - descriptorMalignant neoplasm of prostateMeasurementMeasuresMessenger RNAMethodologyMethodsMicroRNAsMicroscopyMolecularMonitorNanotechnologyNucleic AcidsNucleotidesOligonucleotidesPathologic ProcessesPatientsPhenotypePlayPolymerase Chain ReactionProcessProductionPropertyProstate-Specific AntigenProteinsRNARNA SequencesRelative (related person)ReporterResearchResearch PersonnelRoleSignal TransductionSmall Business Innovation Research GrantSourceSurfaceSystemTechniquesTechnologyTestingTetracyclinesTimeTransfectionUrineUrsidae Familybasecancer cellcommercializationcytotoxicdesignhuman diseaseimprovedinterestlight microscopynanonanoparticlenew technologynew therapeutic targetnovelnucleasepublic health relevanceresearch studysenescencesmall moleculesuccesstime usetool
项目摘要
DESCRIPTION (provided by applicant): Under the auspices of this small business innovation research (SBIR) grant, AuraSense LLC will develop a novel nanotechnology, "Nano-flares", for the detection of low abundance microRNA (miR) species in living cells in real-time. MicroRNAs are short (~22 nucleotides in length) non-protein coding RNA sequences that play a key role in regulating diverse cellular processes that occur, for instance, during development or during malignant transformation. Unique miRs are being evaluated as novel biomarkers for myriad diseases, and explored as novel therapeutic targets. No existing commercial technology is capable of detecting intracellular RNA target sequences, including miRs, in real-time in living cells. Nano-flares technology provides new opportunities for the detection of intracellular miR targets and will identify how these unique RNAs can be more effectively detected, improving our knowledge of miR function, and, ultimately targeted to improve human health. Nano-flare technology is based upon the unique conjugate properties of DNA oligonucleotides which can be densely loaded on the surface of gold nanoparticles (DNA-Au NPs). Importantly, DNA-Au NPs are universally taken up by cells and can be tailored to target specific intracellular RNA target sequences. Upon encountering a target RNA sequence, Nano-flares turn on a fluorescent signal which can be detected in single cells using fluorescent microscopy, or averaged over millions of cells using fluorescence activated cell sorting (FACS). In contrast to methods which employ the polymerase chain reaction (PCR), cells interrogated using the Nano-flares technology are alive and, thus, available for downstream applications. We propose using the Nano-flare technology to detect and quantify miR and messenger RNA (mRNA) sequences in live prostate cancer cells. Importantly, we will develop a cell model where specific miR and mRNA targets can be manipulated with small molecules in order to evaluate the ability of the Nano-flare system to detect and quantify relative changes in high and low abundance target miR. Results obtained with the Nano-flare system will be directly compared to those obtained using PCR techniques, the current commercial benchmark for detection of these targets. Project success will result in a robust platform for the detection of intracellular miR targets using FACS and confocal fluorescent microscopy. By using qPCR to confirm the Nano-flare results, this project will also set new analytical benchmarks for the real-time detection of miR target sequences inside of live cells, and define what 'low abundance' miR represents in single cells and in ensemble measurements. Finally, completion of this study will bring this enabling technology closer to commercialization and increase the potential for researchers and clinicians, ultimately improving patient health.
PUBLIC HEALTH RELEVANCE: Despite the realized and increasing importance of microRNAs in human disease processes, no current methodology exists to detect changes in microRNA levels in live human cells in real-time. Nano-flare technology being developed by AuraSense, LLC will provide this capability, and represents a novel technology that is designed to provide PCR-like phenotypic characterization of intracellular microRNA targets, significantly, in living cells. Successful project completion will provide a unique technological tool for the study of microRNAs to the broader research community, and, ultimately, the clinical community to improve human health.
描述(由申请人提供):在这项小企业创新研究(SBIR)资助的赞助下,AuraSense LLC将开发一种新型纳米技术“纳米耀斑”,用于实时检测活细胞中的低丰度microRNA(miR)物种。MicroRNA是短的(长度约22个核苷酸)非蛋白质编码RNA序列,其在调节例如在发育期间或在恶性转化期间发生的多种细胞过程中起关键作用。独特的miR正在被评估为无数疾病的新生物标志物,并被探索为新的治疗靶点。没有现有的商业技术能够在活细胞中实时检测细胞内RNA靶序列,包括miR。纳米耀斑技术为检测细胞内miR靶点提供了新的机会,并将确定如何更有效地检测这些独特的RNA,提高我们对miR功能的认识,并最终靶向改善人类健康。Nano-flare技术是基于DNA寡核苷酸的独特共轭特性,其可以密集地负载在金纳米颗粒(DNA-Au NPs)的表面上。重要的是,DNA-Au纳米颗粒普遍被细胞吸收,并且可以被定制为靶向特定的细胞内RNA靶序列。当遇到靶RNA序列时,纳米耀斑打开荧光信号,该荧光信号可以使用荧光显微镜在单个细胞中检测到,或者使用荧光激活细胞分选(FACS)在数百万个细胞中进行平均。与采用聚合酶链式反应(PCR)的方法相反,使用Nano-flares技术询问的细胞是活的,因此可用于下游应用。 我们建议使用Nano-flare技术检测和定量活前列腺癌细胞中的miR和信使RNA(mRNA)序列。重要的是,我们将开发一种细胞模型,其中可以用小分子操纵特定的miR和mRNA靶标,以评估Nano-flare系统检测和定量高丰度和低丰度靶标miR相对变化的能力。使用Nano-flare系统获得的结果将直接与使用PCR技术获得的结果进行比较,PCR技术是目前检测这些目标的商业基准。项目的成功将为使用FACS和共聚焦荧光显微镜检测细胞内miR靶点提供一个强大的平台。通过使用qPCR来确认Nano-flare结果,该项目还将为活细胞内miR靶序列的实时检测设定新的分析基准,并定义单细胞和整体测量中的“低丰度”miR代表什么。最后,这项研究的完成将使这项技术更接近商业化,并增加研究人员和临床医生的潜力,最终改善患者的健康。
公共卫生关系:尽管microRNA在人类疾病过程中的重要性已经认识到并日益增加,但目前还没有方法来实时检测活人类细胞中microRNA水平的变化。AuraSense,LLC正在开发的Nano-flare技术将提供这种能力,并且代表了一种新技术,该技术被设计用于在活细胞中显著地提供细胞内microRNA靶标的PCR样表型表征。项目的成功完成将为更广泛的研究界提供一种独特的技术工具,并最终为临床界提供改善人类健康的技术工具。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David A. Giljohann其他文献
Nanoconjugués capables de traverser la barrière hémato-encéphalique
能够穿越血脑屏障的纳米复合物
- DOI:
- 发表时间:
2012 - 期刊:
- 影响因子:0
- 作者:
Chad A. Mirkin;Caroline H. Ko;Alexander H. Stegh;David A. Giljohann;Janina P. Luciano;S. Jensen - 通讯作者:
S. Jensen
Conjugués de nanoparticule de polynucléotide polyvalente en tant que véhicules de distribution pour un agent chimiothérapique
多核苷酸多价纳米粒子结合物与化学药物分配载体
- DOI:
- 发表时间:
2010 - 期刊:
- 影响因子:0
- 作者:
Chad A. Mirkin;David A. Giljohann;W. Daniel;Stephen J. Lippard;Shanta Dhar - 通讯作者:
Shanta Dhar
Structure polynucléotidique réticulée
多核苷酸网状结构
- DOI:
- 发表时间:
2011 - 期刊:
- 影响因子:0
- 作者:
Chad A. Mirkin;C. S. Thaxton;David A. Giljohann;Joshua I. Cutler - 通讯作者:
Joshua I. Cutler
972 CREATION AND CHARACTERIZATION OF A THERAPEUTIC NANOPARTICLE PLATFORM FOR TREATMENT OF BLADDER CANCER: PRELIMINARY IN VITRO RESULTS
- DOI:
10.1016/j.juro.2010.02.1919 - 发表时间:
2010-04-01 - 期刊:
- 影响因子:
- 作者:
Neema Navai;David A. Giljohann;Lee Zhao;Brian T. Helfand;C. Shad Thaxton;Chad A. Mirkin - 通讯作者:
Chad A. Mirkin
Topically Delivered Tumor Necrosis Factor-α–Targeted Gene Regulation for Psoriasis
- DOI:
10.1016/j.jid.2017.04.027 - 发表时间:
2017-09-01 - 期刊:
- 影响因子:
- 作者:
Katherine T. Lewandowski;Rebecca Thiede;Nicholas Guido;Weston L. Daniel;Richard Kang;Mara-Isel Guerrero-Zayas;Mark A. Seeger;Xiao-Qi Wang;David A. Giljohann;Amy S. Paller - 通讯作者:
Amy S. Paller
David A. Giljohann的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David A. Giljohann', 18)}}的其他基金
Topically-delivered Mutation-specific Gene Targeting for Epidermolytic Ichthyosis
局部递送突变特异性基因靶向治疗表皮松解性鱼鳞病
- 批准号:
8710808 - 财政年份:2014
- 资助金额:
$ 20万 - 项目类别:
Topically-delivered Targeted Gene Suppression of Immune Activation in Psoriasis
银屑病免疫激活的局部靶向基因抑制
- 批准号:
8710888 - 财政年份:2014
- 资助金额:
$ 20万 - 项目类别:
相似国自然基金
企业绩效评价的DEA-Benchmarking方法及动态博弈研究
- 批准号:70571028
- 批准年份:2005
- 资助金额:16.5 万元
- 项目类别:面上项目
相似海外基金
An innovative EDI data, insights & peer benchmarking platform enabling global business leaders to build data-led EDI strategies, plans and budgets.
创新的 EDI 数据、见解
- 批准号:
10100319 - 财政年份:2024
- 资助金额:
$ 20万 - 项目类别:
Collaborative R&D
BioSynth Trust: Developing understanding and confidence in flow cytometry benchmarking synthetic datasets to improve clinical and cell therapy diagnos
BioSynth Trust:发展对流式细胞仪基准合成数据集的理解和信心,以改善临床和细胞治疗诊断
- 批准号:
2796588 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Studentship
Elements: CausalBench: A Cyberinfrastructure for Causal-Learning Benchmarking for Efficacy, Reproducibility, and Scientific Collaboration
要素:CausalBench:用于因果学习基准测试的网络基础设施,以实现有效性、可重复性和科学协作
- 批准号:
2311716 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Standard Grant
Benchmarking collisional rates and hot electron transport in high-intensity laser-matter interaction
高强度激光-物质相互作用中碰撞率和热电子传输的基准测试
- 批准号:
2892813 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Studentship
Collaborative Research: SHF: Medium: A Comprehensive Modeling Framework for Cross-Layer Benchmarking of In-Memory Computing Fabrics: From Devices to Applications
协作研究:SHF:Medium:内存计算结构跨层基准测试的综合建模框架:从设备到应用程序
- 批准号:
2347024 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Standard Grant
Collaborative Research: BeeHive: A Cross-Problem Benchmarking Framework for Network Biology
合作研究:BeeHive:网络生物学的跨问题基准框架
- 批准号:
2233969 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Continuing Grant
FET: Medium: Quantum Algorithms, Complexity, Testing and Benchmarking
FET:中:量子算法、复杂性、测试和基准测试
- 批准号:
2311733 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Continuing Grant
Establishing and benchmarking advanced methods to comprehensively characterize somatic genome variation in single human cells
建立先进方法并对其进行基准测试,以全面表征单个人类细胞的体细胞基因组变异
- 批准号:
10662975 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Collaborative Research: BeeHive: A Cross-Problem Benchmarking Framework for Network Biology
合作研究:BeeHive:网络生物学的跨问题基准框架
- 批准号:
2233968 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Continuing Grant














{{item.name}}会员




